Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir.

“Almirall LLC’s claims of a patent relating to methods for treating acne are invalid because they would be obvious to someone skilled in the field, the Federal Circuit ruled.

The Patent Trial and Appeal Board didn’t err in finding that some claims of Almirall LLC‘s patent were obvious and its determination was supported by enough evidence, the U.S. Court of Appeals for the Federal Circuit ruled in a precedential opinion.”

Sterne, Kessler, Goldstein & Fox’s representation of Amneal Pharmaceuticals LLC was mentioned in the article “Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir.,” published by Bloomberg Law. The team was led by Director Dennies Varughese, Pharm.D., and included Directors Kristina Caggiano Kelly, Adam C. LaRock, and Robert C. Millonig, Ph.D., Counsel Olga A. Partington, Ph.D., and Associate Tyler C. Liu.

Read the full article about Amneal’s win at the Federal Circuit at the link below.